Company Overview
Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
